Alan Nurden: Comparing Antiplatelet and Antithrombin Therapies in Coronary Microcirculation
Alan Nurden, Emeritus Research Director at CNRS, Co-Founder of the French National Reference Centre for Inherited Platelet Disorders (CRPP), shared a post on LinkedIn about a recent article by Joanne L. Mitchell et al., published in Basic Research in Cardiology, adding:
“This provocative manuscript looks in depth at the effects of anti-platelet drugs and at inhibiting thrombin in the context of ischemia-reperfusion injury of the coronary microcirculation of wildtype and diabetic mice.
It comes some 25 years after the identification of the P2Y12 receptor for ADP by Hollopeter et al.
The authors provide insights into both the inhibition of platelet-rich thrombi formation and the potentially negative effects of increased neutrophil infiltration on cardiac damage and/or repair.
For me, this study emphasizes the need to look again at the molecular interactions that occur during thrombus formation under flow using the modern advances in immunofluorescent imaging as illustrated in the recent manuscript by Kusch et al.
I am thinking not only of primary platelet interactions with themselves and fibrin but also their role in thrombo-inflammation and neutrophil migration across the endothelial barrier into inflamed tissue.
We still have much to learn as this manuscript illustrates before truly optimal personalized combined therapies involving different drugs enter clinical practice. This article by Joanne Mitchell and her coworkers is highly recommended.”
1.Title: Comparing anti-platelet and anti-thrombin therapies in the ischaemia–reperfusion injured coronary microcirculation of healthy and diabetic mice
Authours: Joanne L. Mitchell, Juma El-Awaisi, Dean Kavanagh, Bernhard Nieswandt, Robert F. Storey and Neena Kalia
Read the Full Article on Basic Research in Cardiology
2.Title: Platelet-derived integrin- and tetraspanin-enriched tethers exacerbate severe inflammation
Auhtors: Charly Kusch, David Stegner, Lukas J Weiss, Paquita Nurden, Philipp Burkard, Denise Johnson, Wolfgang Bergmeier, Ceylan Onursal, Stefano Navarro, Christian Hackenbroch, Dennis Pfeiffer, Sabrina Ivana Bonfiglio, Mara Meub, Carina Gross, Joachim Schenk, Valeria Fumagalli, Kristina Mott, Markus Bender, Matteo Iannacone, Oliver Andres, Wolfgang Kastenmüller, Katrin G Heinze, Markus Sauer, Harald Schulze, Klaus Ley, Alan T Nurden, Bernhard Nieswandt
Read the Full Article on Science
Find more posts featuring Alan Nurden on Hemostasis Today.
-
Sep 3, 2026, 08:53Jamie’s Journey Through a Decade with Immune Thrombocytopenia – ITP Support Association
-
Sep 3, 2026, 08:00Beth Meneley: When Transfusion Is Not an Option – HBOT for Exceptional Blood Loss Anemia
-
Sep 3, 2026, 06:27Seyed Mehrab Safdari: Unmasking Factor VII Padua to Prevent Unnecessary Therapy and Thrombotic Risk
-
Sep 3, 2026, 04:09Pedro Perez: Are We Entering a New Era in the Treatment of Intermediate-High-Risk PE?
-
Sep 3, 2026, 04:01Marianne Yee: Supporting Families and Transformative Therapies in Sickle Cell Disease
-
Sep 3, 2026, 03:51Strengthening Bleeding Disorders Care in New Zealand – WFH
-
Sep 3, 2026, 03:42Nathan Connell: FDA Approves Rusfertide for Polycythemia Vera
-
Sep 3, 2026, 03:28Katrina Snow: Learning More About Sickle Cell Disease This September
-
Sep 3, 2026, 01:19Himanshu Aggarwal: 1 mg/kg/d Thalidomide Non-Inferior to Standard Dose in Transfusion-Dependent Thalassemia